MENU
+Compare
HRTS
ETF ticker: NASDAQ
AS OF
Jul 23 closing price
Price
$29.15
Change
+$0.65 (+2.28%)
Net Assets
47.9M

HRTS stock forecast, quote, news & analysis

The investment seeks to provide long-term growth of capital... Show more

Category: #Health
HRTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for HRTS with price predictions
Jul 23, 2025

HRTS in downward trend: price may decline as a result of having broken its higher Bollinger Band on July 09, 2025

HRTS broke above its upper Bollinger Band on July 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 11 similar instances where the stock broke above the upper band. In of the 11 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for HRTS turned negative on July 17, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 17 similar instances when the indicator turned negative. In of the 17 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HRTS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 19 cases where HRTS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on July 22, 2025. You may want to consider a long position or call options on HRTS as a result. In of 21 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

HRTS moved above its 50-day moving average on July 22, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HRTS advanced for three days, in of 104 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 55 cases where HRTS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Unitedhealth Group (NYSE:UNH), Merck & Co (NYSE:MRK), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Abbott Laboratories (NYSE:ABT), Amgen (NASDAQ:AMGN), Medtronic plc (NYSE:MDT), Bristol-Myers Squibb Co (NYSE:BMY), Boston Scientific Corp (NYSE:BSX).

Industry description

The investment seeks to provide long-term growth of capital. Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to GLP-1 and the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions. The fund generally is expected to consist of more than 15 companies but not more than 100 companies. The fund is non-diversified.

Market Cap

The average market capitalization across the Tema Heart & Health ETF ETF is 90.26B. The market cap for tickers in the group ranges from 3.51M to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is NOVN at 3.51M.

High and low price notable news

The average weekly price growth across all stocks in the Tema Heart & Health ETF ETF was 1%. For the same ETF, the average monthly price growth was 4%, and the average quarterly price growth was -3%. NTLA experienced the highest price growth at 19%, while ARWR experienced the biggest fall at -13%.

Volume

The average weekly volume growth across all stocks in the Tema Heart & Health ETF ETF was 32%. For the same stocks of the ETF, the average monthly volume growth was 13% and the average quarterly volume growth was 31%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 76
Price Growth Rating: 53
SMR Rating: 73
Profit Risk Rating: 68
Seasonality Score: 5 (-100 ... +100)
View a ticker or compare two or three
HRTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
United Satets
Phone
N/A
Web
www.tema.co